NanoViricides Inc
NNVC1.610USD
+0.030+1.89%
Horário de mercado （ET）Cotações atrasadas em 15 min
25.87MValor de mercado
PerdaP/L TTM
Mais detalhes de NanoViricides Inc Empresa
NanoViricides, Inc. is a clinical-stage company that is creating special purpose nanomaterials for antiviral therapy. Its nanoviricide class of drug candidates and the nanoviricide technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. Its lead drug candidate is NV-387, a broad-spectrum antiviral drug that it plans to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. It is focused on advancing NV-387 into Phase II human clinical trials. Its other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. NV-CoV-2 (API NV-387) is its nanoviricide drug candidate for COVID-19 that does not encapsulate remdesivir. NV-CoV-2-R is its other drug candidate for COVID-19 that is made up of NV-387 with remdesivir encapsulated within its polymeric micelles. It has developed both of its own drug candidates NV-CoV-2 and NV-CoV-2-R independently.
Informações da empresa
Código da empresaNNVC
Nome da EmpresaNanoViricides Inc
Data de listagemAug 12, 2004
CEODr. Anil Diwan, Ph.D.
Número de funcionários7
Tipo de títulosOrdinary Share
Fim do ano fiscalAug 12
Endereço1 Controls Drive
CidadeSHELTON
Bolsa de valoresNYSE American Consolidated
PaísUnited States of America
Código postal06484
Telefone12039376137
Sitehttps://www.nanoviricides.com/
Código da empresaNNVC
Data de listagemAug 12, 2004
CEODr. Anil Diwan, Ph.D.
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Meeta Vyas
Meeta Vyas
Chief Financial Officer
Chief Financial Officer
7.13K
--
Dr. Anil Diwan, Ph.D.
Dr. Anil Diwan, Ph.D.
President, Chief Executive Officer, Executive Chairman of the Board
President, Chief Executive Officer, Executive Chairman of the Board
--
--
Dr. Makarand (Mak) Jawadekar, Ph.D.
Dr. Makarand (Mak) Jawadekar, Ph.D.
Independent Director
Independent Director
--
--
Mr. Theodore Edward (Todd) Rokita, J.D.
Mr. Theodore Edward (Todd) Rokita, J.D.
Independent Director
Independent Director
--
--
Mr. Brian F. Zucker
Mr. Brian F. Zucker
Independent Director
Independent Director
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Meeta Vyas
Meeta Vyas
Chief Financial Officer
Chief Financial Officer
7.13K
--
Dr. Anil Diwan, Ph.D.
Dr. Anil Diwan, Ph.D.
President, Chief Executive Officer, Executive Chairman of the Board
President, Chief Executive Officer, Executive Chairman of the Board
--
--
Dr. Makarand (Mak) Jawadekar, Ph.D.
Dr. Makarand (Mak) Jawadekar, Ph.D.
Independent Director
Independent Director
--
--
Mr. Theodore Edward (Todd) Rokita, J.D.
Mr. Theodore Edward (Todd) Rokita, J.D.
Independent Director
Independent Director
--
--
Mr. Brian F. Zucker
Mr. Brian F. Zucker
Independent Director
Independent Director
--
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: qua, 16 de jul
Atualizado em: qua, 16 de jul
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
The Vanguard Group, Inc.
3.18%
Theracour Pharma, Inc.
2.93%
BlackRock Institutional Trust Company, N.A.
0.99%
Geode Capital Management, L.L.C.
0.96%
Renaissance Technologies LLC
0.66%
Other
91.29%
Investidores
Investidores
Proporção
The Vanguard Group, Inc.
3.18%
Theracour Pharma, Inc.
2.93%
BlackRock Institutional Trust Company, N.A.
0.99%
Geode Capital Management, L.L.C.
0.96%
Renaissance Technologies LLC
0.66%
Other
91.29%
Tipos de investidores
Investidores
Proporção
Investment Advisor
4.91%
Corporation
2.93%
Investment Advisor/Hedge Fund
1.70%
Hedge Fund
0.69%
Individual Investor
0.60%
Venture Capital
0.32%
Research Firm
0.23%
Bank and Trust
0.03%
Other
88.60%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
61
1.83M
11.40%
-362.26K
2025Q1
63
2.05M
12.78%
-124.35K
2024Q4
61
2.03M
12.98%
-23.52K
2024Q3
60
1.91M
13.93%
-126.25K
2024Q2
62
1.91M
16.17%
+50.13K
2024Q1
62
1.74M
14.78%
-267.11K
2023Q4
64
1.76M
14.98%
-214.22K
2023Q3
67
1.72M
14.71%
-264.52K
2023Q2
63
1.75M
15.01%
-221.57K
2023Q1
69
1.77M
15.19%
-341.23K
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
The Vanguard Group, Inc.
510.42K
3.18%
--
--
Mar 31, 2025
Theracour Pharma, Inc.
470.96K
2.93%
--
--
Oct 09, 2024
BlackRock Institutional Trust Company, N.A.
158.75K
0.99%
--
--
Mar 31, 2025
Geode Capital Management, L.L.C.
154.59K
0.96%
+11.28K
+7.87%
Mar 31, 2025
Renaissance Technologies LLC
105.80K
0.66%
-39.90K
-27.39%
Mar 31, 2025
XTX Markets LLC
51.25K
0.32%
+51.25K
--
Mar 31, 2025
Bridgeway Capital Management, LLC
44.04K
0.27%
--
--
Mar 31, 2025
State Street Global Advisors (US)
41.91K
0.26%
--
--
Mar 31, 2025
City National Rochdale, LLC
30.54K
0.19%
--
--
Mar 31, 2025
Jawadakar (Makarand)
30.50K
0.19%
--
--
Oct 09, 2024
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Nome
Proporção
iShares Core S&P Total U.S. Stock Market ETF
0%
Dimensional US Core Equity 1 ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
Proporção0%
Dimensional US Core Equity 1 ETF
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
